Transdermal Buprenorphine for Pain Management in Children

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2021 Sep 27

PMID 34567202

Citations 1

Authors

Giorgio Attina

Alberto Romano

Silvia Triarico

Stefano Mastrangelo

Palma Maurizi

Antonio Ruggiero

Affiliations

Soon will be listed here.

Abstract

Pain is one of the main symptoms reported by sick children, particularly by those suffering from cancer. Opioids are very useful in controlling this symptom but they are burdened with significant side effects that limit their use in children. Buprenorphine is a strong opioid that, due to its particular pharmacological characteristics, ensures excellent pain relief with fewer side effects than other opioids. The transdermal formulation allows for good pain control associated with optimal compliance by patients and few limitations on daily life. Unfortunately, transdermal buprenorphine use remains off-label for the control of chronic pain in children; therefore, it is desirable that new studies can validate its use in the paediatric population. This review aims to analyse the clinical advantages of transdermal buprenorphine in the paediatric population and the possible side effects registered in daily clinical practice.

Citing Articles

The Challenge of Managing Neuropathic Pain in Children and Adolescents with Cancer.

Coluzzi F, Stefano G, Scerpa M, Rocco M, Di Nardo G, Innocenti A Cancers (Basel). 2025; 17(3).

PMID: 39941827 PMC: 11816330. DOI: 10.3390/cancers17030460.

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.

Mastrangelo S, Rivetti S, Triarico S, Romano A, Attina G, Maurizi P Int J Mol Sci. 2021; 22(23).

PMID: 34884452 PMC: 8657961. DOI: 10.3390/ijms222312648.

References

Mastrangelo S, Capozza M, Triarico S, Attina G, Maurizi P, Romano A . Opioid transdermal delivery system: a useful method for pain management in children. Ann Transl Med. 2021; 9(2):185. PMC: 7867936. DOI: 10.21037/atm-20-2619. View

Virk M, Arttamangkul S, Birdsong W, Williams J . Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009; 29(22):7341-8. PMC: 2752300. DOI: 10.1523/JNEUROSCI.3723-08.2009. View

Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E . Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006; 96(5):627-32. DOI: 10.1093/bja/ael051. View

Budd K . Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl. 2003; (133):9-14; discussion 23-4. View

White L, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish T . Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018; 120(4):668-678. DOI: 10.1016/j.bja.2017.11.086. View

Pick C, Peter Y, Schreiber S, Weizman R . Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res. 1997; 744(1):41-6. DOI: 10.1016/s0006-8993(96)01069-4. View

Maunuksela E, Korpela R, Olkkola K . Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth. 1988; 60(1):48-55. DOI: 10.1093/bja/60.1.48. View

Quirk K, Wright J, Marks A, Smith M . Sublingual Buprenorphine for Pediatric Cancer Pain: A Case Report and Review of the Literature. J Pain Symptom Manage. 2020; 60(5):1055-1058. DOI: 10.1016/j.jpainsymman.2020.07.029. View

Begona Delgado-Charro M, Guy R . Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev. 2013; 73:63-82. DOI: 10.1016/j.addr.2013.11.014. View

10.

Ceccarelli I, De Padova A, Fiorenzani P, Massafra C, Aloisi A . Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience. 2006; 140(3):929-37. DOI: 10.1016/j.neuroscience.2006.02.044. View

11.

Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C . Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage. 2007; 34(5):532-8. DOI: 10.1016/j.jpainsymman.2007.01.006. View

12.

Davis M . Buprenorphine in cancer pain. Support Care Cancer. 2005; 13(11):878-87. DOI: 10.1007/s00520-005-0849-9. View

13.

Michel E, Anderson B, Zernikow B . Buprenorphine TTS for children--a review of the drug's clinical pharmacology. Paediatr Anaesth. 2010; 21(3):280-90. DOI: 10.1111/j.1460-9592.2010.03437.x. View

14.

Zernikow B, Michel E, Craig F, Anderson B . Pediatric palliative care: use of opioids for the management of pain. Paediatr Drugs. 2009; 11(2):129-51. DOI: 10.2165/00148581-200911020-00004. View

15.

Sittl R, Likar R, Poulsen Nautrup B . Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005; 27(2):225-37. DOI: 10.1016/j.clinthera.2005.02.012. View

16.

Timeus F, Crescenzio N, Longoni D, Doria A, Foglia L, Pagliano S . Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: a multicentre study. PLoS One. 2014; 9(7):e101948. PMC: 4090189. DOI: 10.1371/journal.pone.0101948. View

17.

Haupt T, Smyth M, Gregoire M . A Scoping Review of Transdermal Buprenorphine Use for Non-surgical Pain in the Pediatric Population. Cureus. 2019; 11(10):e5954. PMC: 6874292. DOI: 10.7759/cureus.5954. View

18.

Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L . Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005; 94(6):825-34. DOI: 10.1093/bja/aei145. View

19.

Likar R, Sittl R . Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg. 2005; 100(3):781-785. DOI: 10.1213/01.ANE.0000145066.06538.20. View

20.

Raffa R, Haidery M, Huang H, Kalladeen K, Lockstein D, Ono H . The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014; 39(6):577-83. DOI: 10.1111/jcpt.12196. View